Definium Therapeutics says Phase 3 Voyage trial meets primary endpoint for DT120 ODT in generalized anxiety disorder

• Definium Therapeutics reported positive topline results from its Phase 3 Voyage trial of DT120 ODT in generalized anxiety disorder.
• The study met the primary endpoint, showing a clinically meaningful reduction in anxiety symptoms versus placebo.
• Key secondary measures also improved, with benefits seen quickly and sustained through Week 12.
• DT120 ODT was generally well tolerated, with no new safety signals reported.
• Panorama Phase 3 GAD topline results are expected in September, following this readout and a prior positive Phase 3 result in depression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608120700BIZWIRE_USPR_____20260812_BW579720) on August 12, 2026, and is solely responsible for the information contained therein.